Formation Bio recently appointed Dr. Michael Ehlers as chief scientific officer and head of research and development.

NEW YORK, June 9, 2025 /PRNewswire/ -- Formation Bio, an AI-driven pharmaceutical company focused on accelerating drug development, today announced the appointment of its first class of Entrepreneurs ...

NEW YORK, June 9, 2026 /PRNewswire/ -- Formation Bio, an AI-native pharma company, today announced dosing of the first participant in a Phase 1, first-in-human (FIH) clinical trial of BLKR201. The ...

NEW YORK, Sept. 18, 2025 /PRNewswire/ -- Formation Bio, the AI-native pharmaceutical company revolutionizing drug development, today announced the appointment of four world-class leaders to its senior ...

Add Yahoo as a preferred source to see more of our stories on Google. Canadian PM Trudeau tours a Sanofi facility in Toronto (Reuters) - AI-based drug developer Formation Bio said on Wednesday that it ...

Formation Bio Inc., a startup using artificial intelligence to speed up drug development, today announced that it has closed a mammoth $372 million investment. Andreessen Horowitz led the Series D ...

(RTTNews) - French drug major Sanofi (SNYNF, SNY) announced Tuesday a collaboration with Formation Bio and AI research and deployment company OpenAI to build AI-powered software to accelerate drug ...

Formation Bio CEO Benjamine Liu joins 'Fast Money' as Formation comes in at #37 on the Disruptor 50 list. Got a confidential news tip? We want to hear from you. Sign up for free newsletters and get ...

Formation Bio Inc. acquired ex-China rights to Lynk Pharmaceuticals Co. Ltd.’s oral TYK2-inhibitor, LNK-01006, for up to $605 million. The phase I-ready central nervous system (CNS) candidate will be ...

Formation Bio has acquired the global rights, excluding in Greater China, to LNK01006, a highly selective tyrosine kinase 2 (TYK2) inhibitor from Lynk Pharmaceuticals. This next-generation central ...

Formation Bio Inc. has licensed worldwide rights to Imidomics Inc.’s potentially first-in-class anti-CD226 monoclonal antibody (mAb). The program has received IND clearance and will be advanced by ...